Exozymes Inc. (EXOZ): who owns it and who trades it
As of Oct 30, 2026, EXOZ insiders reported 3 open-market sales worth $34.9K and 5 purchases worth $6.4K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Damien Alan Perriman (Chief Commercial Officer), with $19.4K.
Latest filing Oct 30, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, EXOZ insiders reported $6.4K of open-market purchases and $34.9K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | Damien Alan Perriman | Chief Commercial Officer | Sale | 3,729 | $5.21 | $19.4K | Form 4 |
| Aug 26, 2026 | Michael Heltzen | CEO | Purchase | 251 | $7.35 | $1.8K | Form 4 |
| Aug 26, 2026 | Michael Heltzen | CEO | Purchase | 250 | $7.60 | $1.9K | Form 4 |
| Aug 26, 2026 | Michael Heltzen | CEO | Purchase | 4 | $7.58 | $30 | Form 4 |
| Aug 25, 2026 | Michael Heltzen | CEO | Purchase | 100 | $7.50 | $750 | Form 4 |
| Aug 25, 2026 | Michael Heltzen | CEO | Purchase | 250 | $7.52 | $1.9K | Form 4 |
| Apr 9, 2026 | Tyler Paz Korman | Chief Scientific Officer | Sale | 750 | $10.53 | $7.9K | Form 4 |
| Apr 8, 2026 | Tyler Paz Korman | Chief Scientific Officer | Sale | 750 | $10.04 | $7.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Damien Alan Perriman | Chief Commercial Officer | – | $19.4K | Oct 12, 2026 |
| Tyler Paz Korman | Chief Scientific Officer | – | $15.4K | Apr 9, 2026 |
| Michael Heltzen | Chief Executive Officer | $6.4K | – | Aug 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EXOZ short interest
Low short interest. 0.2% of EXOZ shares are sold short: about 1 share in 519. Over the last 12 reports the number of shares short went up 49%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17,877 EXOZ shares were sold short, 0.2% of the shares outstanding, up 1.3% from the report before. At the average daily volume of 15,318 shares, buying them all back would take about 1.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17,877 | 0.19% | +1% | 15,318 | 1.2 |
| Oct 15, 2026 | 17,654 | 0.19% | -4% | 9,163 | 1.9 |
| Sep 30, 2026 | 18,469 | 0.20% | -10% | 8,995 | 2.0 |
| Sep 15, 2026 | 20,419 | 0.22% | -6% | 6,641 | 3.1 |
| Aug 31, 2026 | 21,807 | 0.23% | +12% | 4,575 | 4.8 |
| Aug 14, 2026 | 19,516 | 0.21% | -11% | 5,311 | 3.7 |
| Jul 31, 2026 | 21,892 | 0.26% | +12% | 8,340 | 2.6 |
| Jul 15, 2026 | 19,579 | 0.23% | +25% | 19,312 | 1.0 |
| Jun 30, 2026 | 15,720 | 0.19% | +6% | 10,596 | 1.5 |
| Jun 15, 2026 | 14,786 | 0.17% | -2% | 7,865 | 1.9 |
| May 29, 2026 | 15,037 | 0.18% | +26% | 4,759 | 3.2 |
| May 15, 2026 | 11,977 | 0.14% | -5% | 2,386 | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Exozymes company events
Exozymes filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 9, 2026.
- Oct 9, 2026AnnouncementAttached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, dated as of October 6, 2026, that may be provided to investment bankers and other offering participants and current and potential investors in securities of the Company. Filing
- Sep 18, 2026AnnouncementThe Company determined to hold its 2026 annual meeting on November 13, 2026, and plans to distribute its proxy statement and proxy to the shareholders on or about September 28, 2026. Filing
- Jul 1, 2026AgreementEXoZymes Inc. entered into a Placement Agent Agreement, with Public Ventures LLC, doing business as MDB Capital, as the exclusive placement agent pursuant to which the Company authorized the sale to an investor of up to an aggregate of 35,555 units, consisting of 71,110 shares of its common stock… Filing
- Jun 26, 2026AnnouncementShared information with investors. Filing
- Jun 17, 2026AgreementUnderwritten Offering eXoZymes Inc. entered into an Underwriting Agreement, dated as of June 5, 2026, with Public Ventures LLC, doing business as MDB Capital, as the sole underwriter and book runner, pursuant to which the Company issued and sold, in a firm commitment underwritten offering, an… Filing
- Jun 8, 2026AgreementEXoZymes Inc. entered into (i) an Underwriting Agreement, dated as of June 5, 2026, with MDB Capital, as the sole underwriter and book runner, pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten offering an aggregate of 592,270 shares of common stock, $0.000001… Filing
- May 7, 2026AnnouncementAttached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, as of May 7, 2026, that is being provided to the potential underwriters and other offering participants and investors for a proposed public offering of securities by the Company. Filing
- Apr 10, 2026AnnouncementAttached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, as of April 10, 2026, that is being provided to the potential underwriters and other offering participants for the proposed offering of securities by the Company. Filing
- Mar 31, 2026AnnouncementAttached is an updated Investor Presentation of eXoZymes Inc., a Nevada corporation, as of March 30, 2026, in connection with its NCTx business. Filing
- Feb 5, 2026AnnouncementAttached is a press release dated January 29, 20226, announcing the advancing commercial readiness of the initial NCT pilot run. Filing
- Dec 12, 2025AnnouncementAttached is a press release eXoZymes Inc. dated December 11, 2025, related to the scale up of NCT production using exozymes. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Exozymes financials
Questions about Exozymes Inc. (EXOZ) stock
Are EXOZ insiders buying or selling?
In the last 12 months, EXOZ insiders reported 5 open-market purchases worth $6.4K and 3 sales worth $34.9K. The latest trade was on Oct 12, 2026. See every trade.
What is the short interest in EXOZ?
As of Oct 30, 2026, 17,877 EXOZ shares were sold short, 0.2% of the shares outstanding, up 1.3% from the report before. At the average daily volume of 15,318 shares, buying them all back would take about 1.2 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.